The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

Sudden cardiac death (SCD) is the most devastating complication of hypertrophic
cardiomyopathy (HCM). Although the annual rate of SCD in the general HCM population is< …

Background An electrocardiographic (ECG) screening test has been developed to identify
patients being considered for a totally subcutaneous implantable cardioverter-defibrillator (S …

Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) does not
require the insertion of any leads into the cardiovascular system. Objective The aims of the …

Background The subcutaneous implantable cardioverter defibrillator (S‐ICD) has been
developed to avert risks associated with transvenous defibrillator leads. The technology is …

Background Subcutaneous implantable cardioverter-defibrillator (S-ICD) is a promising
option for patients with hypertrophic cardiomyopathy (HCM). Patients with HCM can present …

Aims Subcutaneous implantable cardioverter-defibrillator (S-ICD) can avoid important
complications associated with transvenous leads in patients with inherited primary …

Subcutaneous ICD in Dialysis Patients Background Although the subcutaneous ICD (S‐
ICD®) is an attractive alternative in patients with end‐stage renal disease (ESRD), data on S …

Implantable cardioverter-defibrillators (ICDs) have revolutionized the treatment of acquired
or inherited cardiac diseases associated with a high risk of sudden cardiac death due to …

Background—The features of the hypertrophic cardiomyopathy (HCM) ECG make it a
challenge for subcutaneous implantable cardioverter-defibrillator (S-ICD) screening. We …